Addition of Bevacizumab to Chemo for Small-Cell Lung Cancer Fails to Improve Outcomes

Share this content:

the Cancer Therapy Advisor take:

According to a recent study published in the journal Annals of Oncology, researchers have found that the addition of bevacizumab at a dose of 7.5mg/kg to chemotherapy after induction did not improve outcome in previously untreated patients with extensive small-cell lung cancer (SCLC).

For this phase II-III study, researchers sought to evaluate the efficacy and safety of adding bevacizumab to chemotherapy following induction chemotherapy in patients with extensive SCLC.

Researchers enrolled 147 patients to receive two induction cycles of chemotherapy. Of those, 74 were randomly assigned 1:1 to receive four additional cycles of either chemotherapy alone or chemotherapy plus bevacizumab 7.5mg/kg, followed by bevacizumab alone until disease progression or unacceptable toxicity.

Results showed that disease control did not differ between the two groups at the end of the fourth cycle (89.2% versus 91.9% of patients remaining responders in chemotherapy alone versus chemotherapy plus bevacizumab groups, respectively).

In addition, median progression-free survival did not significantly differ either (5.5 months versus 5.3 months in chemotherapy alone versus chemotherapy plus bevacizumab groups, respectively).

In regard to safety, Grade ≥2 hypertension and Grade ≥3 thrombotic events occurred in 40% and 11% of patients, respectively, in the bevacizumab group.

Lung-RADS can reduce false-positive rate for lung cancer screening.
Addition of bevacizumab to chemotherapy after induction did not improve outcome in previously untreated extensive SCLC.
This randomized Phase II-III trial sought to evaluate the efficacy and safety of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell lung cancer (SCLC). Administering 7.5mg/kg Bev after induction did not improve outcome in extensive SCLC patients.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters